Sara Secall

Sara joined Inveready in 2013 and is responsible for building the Biotech Portfolio. While at Inveready she has led transactions such as AVX Pharma and Edesa Biotech (both exited) and sits at the board of companies such as Oxolife, Aptatargtets and Oncostellae. Sara has an extensive international career in technology investing. She has worked extensively in the USA, Latin America and Europe.